Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Cash from Investing Activities (2023 - 2024)

Sagimet Biosciences has reported Cash from Investing Activities over the past 2 years, most recently at $9.8 million for Q4 2024.

  • Quarterly results put Cash from Investing Activities at $9.8 million for Q4 2024, up 150.2% from a year ago — trailing twelve months through Dec 2024 was -$61.7 million (down 590.33% YoY), and the annual figure for FY2025 was $4.6 million, up 107.39%.
  • Cash from Investing Activities for Q4 2024 was $9.8 million at Sagimet Biosciences, up from $624000.0 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for SGMT hit a ceiling of $19.4 million in Q1 2023 and a floor of -$75.2 million in Q2 2024.